Successful treatment of myelodysplastic syndrome and chronic hepatitis C using combined peginterferon-α-2b and ribavirin therapy

Hepatology Research

Volumn 44, Issue 11, 2014, Pages 1159-1164

  Maruyama, Shigeo ^a   Koda, Masahiko ^b   Oi, Shinnji ^c   Murawaki, Yoshikazu ^b  

^a Maruyama Medical Clinic   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c MATSUE RED CROSS HOSPITAL   (Japan)

Author keywords

Extrahepatic manifestation; Hepatitis C virus; Interferon therapy; Myelodysplastic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC HEPATITIS C; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ECHOGRAPHY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 2; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMAGE GUIDED BIOPSY; KARYOTYPE 45,X; KARYOTYPE 46,XY; LABORATORY TEST; LIVER BIOPSY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MEGAKARYOCYTE; NEUTROPHIL; PANCYTOPENIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84914151055     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12274     Document Type: Article

References (17)

1. Jacoby RF, Brasitus TA. Myelodysplastic syndrome and pancytopenia in a patient with non-A, non-B chronic active hepatitis. J Clin Gastroenterol 1991; 13: 211-213.
2. Klco JM, Geng B, Brunt EM etal. Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility. Am J Hemtol 2010; 85: 106-110.
3. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541.
4. Greenberg PL, Tuechler H, Schanz J etal. Revised international prognostic scoring system for myelodysplastisc syndromes. Blood 2012; 120: 2454-2465.
5. United Kingdom Cancer Cytogenetics Group. Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chrom Cancer 1992; 5: 83-88.
6. Wiktor A, Rybicki BA, Poao Z etal. Clinical significance of Y chromosome loss in hematologic disease. Genes Chrom Cancer 2000; 27: 11-16.
7. Holmes RI, Keating MJ, Cork A, Trujillo JM, McCredic KB, Freireich EJ. Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. Cancer Genet Cytogenet 1975; 17: 269-278.
8. Agnello V, Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-352.
9. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F. Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequence by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996; 103: 414-421.
10. Lerat H, Rumin S, Habersetzer F etal. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998; 91: 3841-3849.
11. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2000; 20: 85-102.
12. Iga D, Tomiyama M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-α therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 2005; 75: 417-423.
13. Takezako N, Shikai T, Tanimura A etal. Myelodysplastic syndrome accompanied by Evans sydrome. Jpn J Clin Hematol 2003; 44: 396-400.
14. Chiao EY, Engels EA, Kramer JR etal. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120908 US veterans with hepatitis C virus infection. Arch Intern Med 2009; 169: 357-363.
15. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 2006; 107: 451-458.
16. Massaro P, Foa P, Pomati M etal. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126-128.
17. Kiladjian JJ, Cassinat B, Chevret S etal. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.